1,2-Disubstituted Heterocyclic Compounds
AssigneeEnVivo Pharmaceuticals, Inc.
InventorsAmy Ripka, Gideon Shapiro, Richard Chesworth
Life of this patent
Estimating the term…
Abstract
1,2-disubstituted heterocyclic compounds which are inhibitors of phosphodiesterase 10 are described. Also described are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. Among the disorders which may be treated are neurological, neurodegenerative and psychiatric disorders including, but not limited to, those associated with cognitive deficits or schizophrenic symptoms.
Claims2
A compound of Formula (I) or (II) or (III) or pharmaceutically acceptable salt thereof
- Wherein:
- HET is a heterocyclic ring selected from Formulas A1-A26 and A29-42 below
- and the left most radical is connected to the X group;
- W is selected from halogen, cyano, nitro, alkoxy, amino, alkylamino, dialkylamino, carboxy, amido, alkylamido, and dialkylamido;
- X is selected from C3-C8 alkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted C4-C7 cycloalkylalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl;
- Y is a bond or a divalent linker group selected from —CH2—, —O—, —SO2—, —CH2O—, —OCH2— and —CH2CH2— with the rightmost radical of the Y group connected to the Z substituent;
- Z is optionally substituted heteroaryl;
- R1a is selected from C1-C4 alkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted C4-C7 cycloalkylalkyl and optionally substituted C4-C7 alkoxyalkyl;
- R1b is selected from C1-C4 alkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted C4-C7 cycloalkylalkyl and optionally substituted C4-C7 alkoxyalkyl;
- Each R2 is independently selected from C1-C4 alkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted C4-C7 cycloalkylalkyl and optionally substituted C4-C7 alkoxyalkyl, or two R2 groups taken together form a 3-6 membered cycloalkyl ring;
- R3 and R4 are independently selected from C1-C4 alkyl, CF3, optionally substituted C3-C6 cycloalkyl, or R3 and R4 taken together form a 3-6 membered cycloalkyl ring;
- R5 is selected from C1-C4 alkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted C4-C7 cycloalkylalkyl and optionally substituted C4-C7 alkoxyalkyl;
- R6 is selected from hydrogen, C1-C6 alkyl, optionally substituted C3-C6 cycloalkyl and optionally substituted C3-C6 cycloalkylalkyl;
- R7 is selected from hydrogen, C1-C4 alkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted C4-C7 cycloalkylalkyl and optionally substituted C4-C7 alkoxyalkyl;
- n is independently selected from 1 and 2.
-117. (canceled)
Dependencies are inferred from the claim text.